Abstract Number: 1367 • ACR Convergence 2024
Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…Abstract Number: 1676 • ACR Convergence 2024
Changing Patients’ Mindsets About Non-Severe Side Effects of Methotrexate: A Randomized Controlled Trial
Background/Purpose: Although methotrexate (MTX) is a first-line treatment for inflammatory rheumatic diseases, side effects can lead to poor adherence and persistence. A novel intervention involves…Abstract Number: 2166 • ACR Convergence 2024
Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a life-long disease that often requires escalation of therapy to achieve disease control. The goal of this project was…Abstract Number: 2419 • ACR Convergence 2024
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…Abstract Number: 0359 • ACR Convergence 2024
SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients
Background/Purpose: Spondyloarthritis (SpA) significantly affects patients' quality of life (QoL). Current tools in routine medical practice primarily focus on assessing disease activity, neglecting the broader…Abstract Number: 0600 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…Abstract Number: 1028 • ACR Convergence 2024
Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care…Abstract Number: 1253 • ACR Convergence 2024
Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Background/Purpose: Patients with SLE often have concomitant FM or symptoms similar to FM, including chronic pain, fatigue, sleep disturbance, and/or depression, potentially distinct from immune-mediated…Abstract Number: 1380 • ACR Convergence 2024
Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
Background/Purpose: Pain is a crucial symptom for patients with RA; early and effective treatment can help alleviate it.1 In this post hoc analysis, we investigated…Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…Abstract Number: 2168 • ACR Convergence 2024
Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Background/Purpose: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by disease modifying antirheumatic drug (DMARD) therapies. Early treatment of…Abstract Number: 2448 • ACR Convergence 2024
Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function
Background/Purpose: Multiple patient-reported outcomes (PROs) have been utilized to capture the burden of Systemic Sclerosis (SSc), including the Health Assessment Questionnaire Disability Index (HAQ-DI), Cochin…Abstract Number: 0362 • ACR Convergence 2024
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…Abstract Number: 0601 • ACR Convergence 2024
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…Abstract Number: 1040 • ACR Convergence 2024
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 43
- Next Page »